GlaxoSmithKline plc (GSK) Shares Rating Restated by JPMorgan Chase & Co.

GlaxoSmithKline plc (GSK) Shares Rating Restated by JPMorgan Chase & Co.

GlaxoSmithKline plc (LON:GSK)‘s stock had its “neutral” rating restated by investment analysts at JPMorgan Chase & Co. in a research report issued on Tuesday. They presently have a GBX 1,670 ($20.99) target price on the stock. JPMorgan Chase & Co.’s target price suggests a potential upside of 0.63% from the company’s current price.

A number of other equities analysts also recently commented on the company. BNP Paribas restated an “underperform” rating and issued a GBX 1,520 ($19.10) price objective on shares of GlaxoSmithKline plc in a report on Tuesday. Societe Generale restated a “sell” rating and issued a GBX 1,300 ($16.34) price objective on shares of GlaxoSmithKline plc in a report on Thursday, March 23rd. Berenberg Bank set a GBX 1,890 ($23.75) price objective on GlaxoSmithKline plc and gave the stock a “neutral” rating in a report on Monday, March 20th. HSBC Holdings plc restated a “buy” rating and issued a GBX 1,970 ($24.76) price objective on shares of GlaxoSmithKline plc in a report on Wednesday, March 15th. Finally, Kepler Capital Markets set a GBX 1,500 ($18.85) price objective on GlaxoSmithKline plc and gave the stock a “sell” rating in a report on Thursday, March 9th. Three research analysts have rated the stock with a sell rating, twelve have given a hold rating and eight have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of GBX 1,743.82 ($21.92).

GlaxoSmithKline plc (LON:GSK) traded down 1.16% during midday trading on Tuesday, reaching GBX 1659.50. The company had a trading volume of 12,105,244 shares. The firm’s market capitalization is GBX 80.77 billion. The firm’s 50-day moving average price is GBX 1,655.77 and its 200 day moving average price is GBX 1,596.31. GlaxoSmithKline plc has a 12 month low of GBX 1,363.00 and a 12 month high of GBX 1,745.56.

The firm also recently disclosed a dividend, which will be paid on Thursday, April 13th. Shareholders of record on Thursday, February 23rd will be paid a dividend of GBX 23 ($0.29) per share. This represents a yield of 1.47%. The ex-dividend date of this dividend is Thursday, February 23rd. This is a positive change from GlaxoSmithKline plc’s previous dividend of $19.00.

In other GlaxoSmithKline plc news, insider Victoria Whyte sold 4,820 shares of the firm’s stock in a transaction that occurred on Thursday, February 9th. The stock was sold at an average price of GBX 1,576 ($19.81), for a total transaction of £75,963.20 ($95,467.14). Also, insider Moncef Slaoui acquired 56 shares of the stock in a transaction on Tuesday, March 7th. The shares were acquired at an average price of GBX 2,072 ($26.04) per share, with a total value of £1,160.32 ($1,458.24). In the last 90 days, insiders have acquired 471 shares of company stock valued at $786,697 and have sold 52,038 shares valued at $84,442,106.

GlaxoSmithKline plc Company Profile

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

Related posts

Leave a Comment